BioPhausia AB

BioPhausia AB (BioPhausia) is a specialty pharmaceutical company, engaged in the provision of cost-effective pharmaceuticals. The company is in the process of building a well-balanced product portfolio, containing original pharmaceuticals as well as in-licensed products, Prescription Products, OTC Products, Veterinary Products, Parallel-Imported Products and generics. It markets and sells generic products through the subsidiary BMM Pharma. Its niche and original products includes RescueFlow is a small volume resuscitation drug, the product is a volume substitution solution given intravenously in trauma situations for a fast and long lasting effect on blood volume; GlycoVisc which is a patented formula with the treatment objective of relieving pain and increasing mobility in elderly patients with arthritic joint disorders; Mollipect is indicated for the treatment of cough. BioPhausia is headquartered Stockholm, Sweden.

Street: 
Blasieholmsgatan 2
City: 
Stockholm
Postcode: 
111 48
Federal State : 
Sweden
WebSite: 
www.biophausia.se
Fax: 
46-8-4076439

Company Index Score

Current Index Score Historical Index Score
  • BioPhausia AB currently scores 50 % in the index.
  • BioPhausia AB is currently ranked equal 15 out of a total of 35419 included in the NS Company Index. This is the top 0.042 % of all companies.
  • BioPhausia AB is currently ranked 1 out of 4535 companies. This is in the top 0.022 % percent of Pharmaceutical companies ranked in the index.
  • User perception of the company stands at 0 % percent. This differs 50 % percent over the score attributed to the company by other scoring factors.

Latest tweets